|
|
||||||||
,3

* Animal Production Research, MTT Agrifood Research Finland, FI-31600, Jokioinen, Finland
Natural ASA, N-6160, Hovdebygda, Norway
Department of Animal Science, University of Helsinki, FI-00014, Helsinki, Finland
2 Corresponding author: kevin.shingfield{at}mtt.fi
| ABSTRACT |
|---|
|
|
|---|
Key Words: milk fat trans fatty acid conjugated linoleic acid lactation
| INTRODUCTION |
|---|
|
|
|---|
Postruminal infusion studies have established that trans-10, cis-12 conjugated linoleic acid (CLA) formed during ruminal 18:2n-6 metabolism (Griinari and Bauman, 1999; Palmquist et al., 2005) inhibits milk fat synthesis in the lactating cow (Baumgard et al., 2000, 2001; Peterson et al., 2002). More recent studies have provided further evidence that cis-10, trans-12 CLA (Sæbø et al., 2005) and trans-9, cis-11 CLA (Perfield et al., 2007), which are ruminal biohydrogenation intermediates of 18:2n-6 (Wallace et al., 2007), also exert antilipogenic effects. However, the increases in ruminal outflow of biohydrogenation intermediates known to inhibit milk fat synthesis do not explain entirely diet-induced MFD, with the implication that additional biohydrogenation intermediates or other mechanisms are also involved (Shingfield and Griinari, 2007).
Diets causing MFD modify ruminal lipid metabolism resulting in an increase in milk fat content and flow of trans-10 18:1 at the duodenum (Griinari et al., 1998; Piperova et al., 2002; Loor et al., 2004). Over a wide range of diets, reductions in milk fat synthesis are known to be associated with elevated milk fat trans-10 18:1 concentrations (Loor et al., 2005; Shingfield and Griinari, 2007), with the corollary that this biohydrogenation intermediate is directly or indirectly involved in the regulation of mammary lipogenesis. Postruminal infusions of a relatively pure (95%) preparation of trans-10 18:1 provided the first direct test of the possible role of this biohydrogenation intermediate on mammary lipid metabolism (Lock et al., 2007). Administration of 42.6 g of trans-10 18:1/d over a 4-d period enhanced the concentrations of this isomer in milk fat from 0.47 to 1.11 g/100 g of fatty acids, but had no effect on milk fat synthesis.
Under certain conditions of diet-induced MFD, ruminal outflow of trans-10 18:1 may increase to levels above 90 g/d (Shingfield and Griinari, 2007), and milk fat trans-10 18:1 concentrations can approach or exceed 10 g/100 g of fatty acids (Piperova et al., 2000; Roy et al., 2006; Shingfield et al., 2006), indicating that the supply of trans-10 18:1 at the mammary gland during diet-induced MFD is often several-fold higher than the amounts evaluated previously (Lock et al., 2007). In the current experiment, the role of trans-10 18:1 in the regulation of mammary lipogenesis was further examined based on milk fat responses to postruminal infusions of a mixture of 18:1 fatty acid methyl esters (FAME) supplying 92 g/d of trans-10 18:1.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Lipid Supplements
Trans-10, cis-12 CLA was synthesized from refined safflower oil (Sæbø et al., 2005). The 18:1 FAME supplement was prepared by Natural ASA (Hovdebygda, Norway) using a mixture of CLA methyl esters predominating in cis-9, trans-11 and trans-10, cis-12 as the starting material. The CLA isomer mixture was dissolved in dimethylacetamide and partially hydrogenated to 18:1 FAME in a continuous flow cell hydrogenation apparatus, using palladium as a catalyst.
Lipid supplements were stored at 4°C under oxygen-free nitrogen before infusion. The fatty acid composition of CLA and T181 supplements was determined based on complementary GC-flame-ionization detection, GC-MS, and Ag+ HPLC analysis. Nonesterified fatty acids in the CLA supplement were converted to FAME using 1% (vol/vol) sulfuric acid in methanol at 50°C for 30 min (Shingfield et al., 2003). Methyl esters were quantified using a gas chromatograph (model 6890, Hewlett-Packard, Wilmington, DE) equipped with a flame-ionization detector and a 100-m fused silica capillary column (i.d. 0.25 mm) coated with a 0.2-µm film of cyanopropyl polysiloxane (CP-SIL 88, Chrompack 7489, Middelburg, the Netherlands). Injector and detector temperatures were maintained at 255°C. Total FAME profile in a 2-µL sample volume at a split ratio of 1:50 was determined using a temperature gradient program with hydrogen as the carrier gas operated at constant pressure (137.9 kPa) at a flow rate of 0.5 mL/min (Shingfield et al., 2003). Isomers of 18:1 and 18:2 were further resolved in a separate analysis under isothermal conditions at 170°C (Shingfield et al., 2003). Peaks were identified based on retention time comparisons with authentic standards (GLC #463 and GLC #606, Nu-Chek Prep, Elysian, MN). Methyl esters not contained in commercially available standards were formally identified by GC-MS analysis of 4,4-dimethyloxazoline fatty acid (DMOX) derivatives prepared from FAME by incubation overnight with 2-amino, 2-methyl-1-propanol under a nitrogen atmosphere at 150°C (Shingfield et al., 2006). Impact ionization spectra of DMOX derivatives were obtained using an identical gas chromatograph equipped with a selective quadrupole mass detector (model 5973N, Agilent Technologies Inc., Wilmington, DE), under an ionization energy of 70 eV. Chromatography was achieved using the same temperature gradient applied for the analysis of FAME and helium as the carrier gas (Shingfield et al., 2006). Double bond geometry was determined based on atomic mass unit distances, with an interval of 12 atomic mass units between the most intense peaks of clusters of ions containing n and n-1 carbon atoms being interpreted as cleavage of the double bond between carbon n and n+1 in the fatty acid moiety.
The distribution of CLA isomers in lipid supplements was determined using a HPLC system (model 1090, Hewlett-Packard) equipped with 4 silver impregnated silica columns (ChromSpher 5 Lipids, 250 x 4.6 mm; 5 µm particle size, Varian Ltd., Walton-on-Thames, UK) coupled in series. Methyl esters of CLA were separated under isocratic conditions at 22°C using 0.1% (vol/vol) acetonitrile in heptane at a flow rate of 1 mL/min and monitoring column effluent at 233 and 210 nm (Shingfield et al., 2003). Under these conditions, cis-10, trans-12 and trans-10, cis-12 CLA co-elute (Sæbø et al., 2005), and therefore, the analysis of lipid supplements was repeated using 2.0% (vol/vol) acetic acid in heptane as the mobile phase (Shingfield et al., 2005). Typical injection volumes were 10 to 20 µL, representing <250 µg of lipid. Identification of CLA isomers was performed using commercially available CLA methyl ester standards (Matreya Inc., Pleasant Gap, PA; Sigma, St. Louis, MO) and comparison with the elution order reported in the literature (Delmonte et al., 2005).
Measurements, Sample Collection, and Chemical Analysis
Individual cow intakes were measured daily during each infusion period. Representative samples of TMR and refused feed were composited daily and stored at –20°C. Chemical composition and nutritive value of experimental feeds was determined using reference methods (Shingfield et al., 2001). Milk yield and DM intake were recorded daily throughout the 42-d experiment. Samples of milk for the determination of fat, CP, and lactose were collected from each cow at each milking for the entire experiment. Milk samples treated with preservative (Bronopol, Valio Ltd., Helsinki, Finland) were stored at 4°C until analyzed for milk fat, CP, and lactose by near infrared analysis (Shingfield et al., 2001). Fatty acid composition was determined in untreated samples of milk collected during the last 24 h of each infusion period and composited according to yield. Milk samples for fatty acid determinations were stored at –20°C until submitted for analysis.
Lipid in 1 mL of milk was extracted in duplicate using diethylether and hexane (5:4, by vol) according to reference procedures (IDF 1C:1987; IDF 16C:1987; IDF, 1987). Extracts were combined and evaporated to dryness at 60°C under oxygen-free nitrogen for 1 h. Samples were dissolved in hexane and methyl acetate and transesterified to FAME using freshly prepared methanolic sodium methoxide (Christie, 1982) with modifications (Shingfield et al., 2003). The FAME prepared from samples of milk fat was quantified by GC using the same temperature gradient and isothermal analysis applied to lipid supplements. Methyl esters not contained in commercially available standards were formally identified by GC-MS analysis of DMOX derivatives prepared from milk fat FAME (Shingfield et al., 2006). Analysis of milk fat CLA isomer profile was determined by HPLC using 0.1% (vol/vol) acetonitrile in heptane as the mobile phase. Milk fatty acid composition was expressed as a weight percentage of total fatty acids using theoretical relative response factors (Craske and Bannon, 1988; Ulberth et al., 1999), and milk fat fatty acid content was determined using tritridecanoin (Nu-Chek Prep) as an internal standard (Shingfield et al., 2003). Concentrations of specific conjugated isomers in CLA supplements were calculated based on proportionate peak area responses determined by HPLC and the sum of trans-7, cis-9 CLA, trans-8, cis-10 CLA and cis-9, trans-11 CLA weight percentage determined by GC.
Statistical Analysis
Mean nutrient intake and milk production data measured over the last 48 h of abomasal infusion were evaluated by ANOVA for a 3 x 3 Latin square design using the mixed procedure of SAS (Version 9.1, SAS Institute Inc., Cary, NC) with a model that included the random effects of cow and fixed effects of period and experimental treatment. Milk fatty acid composition data determined in samples collected over the last 24 h of each treatment period were analyzed using the same statistical model. Milk production data collected over the course of the experiment were also subjected to ANOVA for repeated measures using the mixed linear model procedure of SAS with a statistical model that included the fixed effects of diet, time, and their interaction, and the random effects of cow assuming an autoregressive order one covariance structure fitted on the basis of Akaike information and Schwarz Bayesian model-fit criteria. Least squares means are reported and treatment effects declared significant at P < 0.05. Differences between treatments at P < 0.10 were considered as a trend toward significance.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
|
|
9-desaturase (Table 4). Postruminal infusion of the T181 treatment at the abomasum enhanced (P < 0.05) milk fat trans-8, cis-10 CLA and trans-10, trans-12 CLA content and tended (P = 0.06) to increase trans-8, trans-10 CLA and cis-9, trans-11 CLA concentrations (Table 5). Reductions in milk fat synthesis to the T181 supplement were explained by a decrease in the secretion of fatty acids synthesized de novo, whereas the output of long-chain fatty acids was unaffected (Figure 3). Correcting for endogenous concentrations indicated that 40.7 ± 1.41% of trans-10 18:1 administered at the abomasum was apparently transferred to the mammary gland and incorporated into milk fat triacylglycerols (TAG). Relative to the control, infusion of treatment T181 also increased (P < 0.01) trans-11 18:1 and cis-9, trans-11 CLA output in milk. Apparent recovery of infused trans-11 18:1 as the sum of trans-11 18:1 and cis-9, trans-11 CLA in milk averaged 39.4 ± 2.27%. Changes in milk fatty acid secretion indicated that 27.5 ± 2.65% of infused trans-11 18:1 was desaturated and secreted as cis-9, trans-11 CLA in milk fat. | DISCUSSION |
|---|
|
|
|---|
A recent study reported the first direct test of the effect of postruminal infusions of trans-10 18:1 on milk fat synthesis in lactating cows. Even though appreciable amounts of trans-10 18:1 were administered, infusions did not alter mammary lipogenesis (Lock et al., 2007). However, a recent evaluation suggested that the enrichment of trans-10 18:1 in milk from 0.47 to 1.11 g/100 g of fatty acids during postruminal infusions may have been too low for possible effects on mammary lipogenesis to be detected (Kadegowda et al., 2008). Therefore, the effects of administration of higher amounts of trans-10 18:1 at the abomasum as part of a mixture of 18:1 FAME on milk fat synthesis were evaluated in the present experiment.
The T181 supplement was prepared as a mixture of methyl esters to ensure that the supplement was liquid at room temperature, thus improving handling properties. Previous studies have shown that postruminal infusions of the known milk fat inhibitor trans-10, cis-12 CLA as a FFA or FAME results in comparable reductions in milk fat synthesis (de Veth et al., 2004). Rather than using a highly purified trans-10 18:1 preparation, a mixture of 18:1 FAME containing trans-10 and trans-11 as major isomers was used. During diet-induced MFD, increases in ruminal trans-10 18:1 outflow are also accompanied by elevated amounts of trans-11 18:1, trans-12 18:1, cis-11 18:1, and cis-12 18:1 reaching the duodenum (Piperova et al., 2002; Loor et al., 2004), indicating that the composition of the T181 treatment mimics the changes in postruminal 18:1 that occur during diet-induced MFD.
Postruminal infusion of 6.0 g/d of trans-10, cis-12 CLA resulted in a 41.4% reduction in milk fat secretion, consistent with an expected decrease of between 35.8 and 39.2% based on relationships developed using data from several studies (de Veth et al., 2004; Shingfield and Griinari, 2007). Treatment T181 resulted in 21.3 and 19.5% reductions in milk fat content and yield, respectively. Decreases in milk fat were apparent within 48 h and continued until the end of the infusion period. Because the T181 treatment contained a mixture of 18:1 isomers, no direct cause and effect can be established, but strong inferences on the contribution of individual constituent fatty acids to the observed reductions in milk fat to treatment T181 supplement can be drawn based on earlier studies. Treatment T181 supplied 92.1 g/d of trans-11 18:1, but there is clear evidence that this isomer is not involved in mammary lipogenesis in the bovine. Postruminal infusions of a mixture of FFA supplying between 12.5 and 41.4 g/d trans-11 18:1 have been shown to have no effect on milk fat secretion (Griinari et al., 2000; Shingfield et al., 2007; Tyburczy et al., 2008). Incremental inclusion of sunflower oil in grass silage-based diets was shown to enhance trans-11 18:1 flow at the omasum from to 14.9 to 126 g/d, whereas milk fat output remained unchanged (Shingfield et al., 2008). Furthermore, supplementing grass hay-based diets with linseed oil resulted in a significant enrichment of trans-11 18:1 in milk fat from 1.21 to 7.49 g/100 g of fatty acids—changes that were independent of alterations in milk fat synthesis (Roy et al., 2006).
Administration of the T181 supplement also supplied smaller quantities (g/d) of cis-9 18:1 (23.3), cis-10 18:1 (3.24), cis-11 18:1 (3.20), cis-12 18:1 (8.26), trans-8 18:1 (0.86), trans-9 18:1 (4.08), trans-12 18:1 (6.55), and trans-13 18:1 (1.46). Data from earlier experiments indicate that the amount of cis-9 18:1 supplied by treatment T181 would be expected to enhance or maintain rather than inhibit milk fat synthesis (Enjalbert et al., 1998; Romo et al., 2000; Drackley et al., 2007). Evidence from several studies also indicate that milk fat synthesis is not altered in response to postruminal infusions supplying 25.0 to 41.7 g/d of trans-9 18:1 (Rindsig and Schultz, 1974; Tyburczy et al., 2008), 1.4 g/d of cis-10 18:1 (Lock et al., 2007), 12.5 to 28.5 g/d of trans-12 18:1 (Griinari et al., 2000; Shingfield et al., 2007) or 1.2 g/d of trans-13 18:1, 12.4 g/d of cis-11 18:1, and 12.4 g/d of cis-12 18:1 (Shingfield et al., 2007). An established lack of association of MFD with fatty acids supplied at similar or greater amounts than the T181 treatment point toward trans-10 18:1 as the most probable candidate responsible for the inhibitory effects on milk fat synthesis.
Abomasal infusion of trans-10 18:1 was shown to have no effect on milk fat synthesis in lactating cows (Lock et al., 2007), which is in direct contrast to an implied role of trans-10 18:1 for the responses to treatment T181 in this experiment. Infusion of the T181 treatment resulted in the uptake and incorporation of 39.5 g/d of trans-10 18:1 into milk, which is about 6-fold greater than the 6.4 g/d in previous investigations (Lock et al., 2007). A much greater effective dose at the mammary gland in the current experiment arises from both the larger amounts of trans-10 18:1 administered at the abomasum (92.1 vs. 42.6 g/d), and a more efficient transfer of this isomer into milk fat (40.5 vs. 15.0%). Reductions in milk fat synthesis to trans-10, cis-12 CLA are dose-dependent (Baumgard et al., 2001; Peterson et al., 2002; de Veth et al., 2004), and it is probable that apparent discrepancies on the possible role of trans-10 18:1 in the regulation of mammary lipogenesis between studies are related to the availability of this isomer at the mammary gland, as would be implied based on a recent evaluation of the changes in milk fat composition during diet-induced MFD (Kadegowda et al., 2008).
Variations in the recovery of infused trans-10 18:1 in milk fat are difficult to reconcile. Postruminal infusions of partially hydrogenated vegetable oils (PHVO) demonstrated that apparent transfer of trans 18:1 from the abomasum into milk can vary between 27.9 and 45.1% (Gaynor et al., 1994; Romo et al., 2000), whereas isomer-specific determinations indicate a mean transfer of trans-10 18:1 at the omasum or duodenum into milk of 32.1% (Shingfield and Griinari, 2007). Apparent absorption of trans 18:1 between the duodenum and ileum is known to be less for diets containing hydrogenated tallow, and absorption of fatty acids with a melting point above body temperature can, under certain situations, be compromised due to reduced solubility in micelles (Glasser et al., 2008b). Efficient transfer of fatty acids from the small intestine into milk is dependent on the partitioning of a fatty acid into TAG during the assembly of chylomicrons and very low density lipoproteins in the intestinal epithelium (Christie, 1981). Studies on the fate of absorbed trans-10 18:1 are limited, but suggest preferential incorporation into plasma TAG and NEFA (Loor and Herbein, 2003; AbuGhazaleh et al., 2003) and comparable extraction across the mammary gland relative to trans-11 18:1 (Loor and Herbein, 2003), consistent with identical recoveries of these isomers in milk fat for treatment T181. In contrast, indirect comparisons of the effects of postruminal infusions of FFA preparations indicate that trans-9 18:1 and trans-11 18:1 are transferred efficiently from the abomasum into milk with a mean efficiency of 59.7 and 54.3%, respectively (Tyburczy et al., 2008) compared with 15% for trans-10 18:1 (Lock et al., 2007) in cows fed comparable diets. Such differences may reflect the lower melting point of supplements enriched with trans-9 18:1 and trans-11 18:1 (42 to 46°C; Tyburczy et al., 2008) compared with trans-10 18:1 (52 to 53°C; Lock et al., 2007), or the warming of dissolved FFA preparations to 37°C immediately before infusion (Tyburczy et al., 2008).
Recovery of trans-11 18:1 on treatment T181 is comparable to previous estimates of 40% in response to 25 g/d of an equimolar mixture of trans-11 18:1 and trans-12 18:1 (Griinari et al., 2000), is greater than the 28.6% based on postruminal infusion of FFA preparations supplying 29.4 g/d of trans-11 18:1 (Shingfield et al., 2007), but less than recent values reported for greater purity FFA supplements providing 41.4 g/d of trans-11 18:1 (Tyburczy et al., 2008). Extensive analysis of published data suggests that although most C18 fatty acids are apparently transferred from the duodenum into milk at a similar efficiency, there is considerable variation between experiments (Glasser et al., 2008a). It appears plausible that the fatty acid composition and melting point of lipid supplements, in addition to the overall supply of fatty acids in the small intestine may contribute to the variance in the efficiency of trans-10 18:1 transfer from the abomasum into milk. In this regard, it is notable that the melting point of the mixture of 18:1 FAME infused in this experiment (18°C) is substantially lower than that of trans-10 18:1 in FFA form (53°C; Shingfield and Griinari, 2007).
Reductions in milk fat output are known to be associated with increases in ruminal trans-10 18:1 outflow (Shingfield and Griinari, 2007) and milk fat trans-10 18:1 content (Loor et al., 2005; Shingfield and Griinari, 2007). Extrapolations from these reationships infer that the amount of trans-10 18:1 supplied by the T181 treatment could be expected to induce a 30.8% reduction in milk fat secretion, while the increases in milk trans-10 18:1 content to treatment T181 would be accompanied by 32.1 to 36.3% decreases in milk fat yield. However, associations do not establish a direct cause and effect, but also include the contribution due to increases in ruminal outflow of trans-10, cis-12 CLA, cis-10, trans-12 CLA, and trans-9, cis-11 CLA that also inhibit milk fat synthesis in the lactating cow (Baumgard et al., 2000; Sæbø et al., 2005; Perfield et al., 2007). It therefore follows that if a role for trans-10 18:1 as a putative milk fat inhibitor were to hold true, the magnitude of reductions in milk fat yield directly attributable to this isomer on treatment T181 would be lower than predicted. Reductions in milk fat output to treatment T181 are equivalent to predicted decreases to postruminal infusions of 1.9 to 2.2 g/d of trans-10, cis-12 CLA (de Veth et al., 2004; Shingfield and Griinari, 2007), indicating that potential antilipogenic effects attributable to trans-10 18:1 would be 40 to 50 fold lower than trans-10, cis-12 CLA.
Infusion of the CLA treatment resulted in a reduction in the secretion of both short and long chain fatty acids, consistent with trans-10, cis-12 CLA reducing mammary abundance of mRNA encoding for key lipogenic enzymes involved in fatty acid uptake and transport, de novo fatty acid synthesis, and TAG synthesis (Baumgard et al., 2002; Harvatine and Bauman, 2006). In contrast, reductions in milk fat yield to treatment T181 were confined to decreases in the secretion of fatty acids synthesized de novo. Previous studies have also demonstrated that decreases in milk fat output to postruminal infusions of PHVO are due to the effects on de novo fatty acid synthesis (Gaynor et al., 1994; Romo et al., 2000). Milk fat composition responses to postruminal infusions of trans 18:1 are often variable and known to be isomer dependent. Administration of trans-9 18:1 (Rindsig and Schultz, 1974) and trans-10 18:1 (Lock et al., 2007) had no effect on milk fat 12:0, 14:0, and 16:0 content, whereas a mixture of fatty acids enriched in trans-11 18:1 and trans-12 18:1 decreased concentrations of fatty acids synthesized de novo, which was accompanied by an increase in the secretion of preformed fatty acids (Shingfield et al., 2007). Possible mechanisms underlying the response to treatment T181 remain unclear, but it has been postulated that reductions in milk fat to postruminal infusions of PHVO are potentially mediated via an inhibition of mammary acyl transferase activity and lowered synthesis of milk fat TAG (Gaynor et al., 1994; Romo et al., 2000).
Treatment T181 supplied 92.1 g/d of trans-11 18:1 and enhanced milk fat trans-11 18:1 and CLA concentrations. Concentration ratios of product versus product plus substrate for
9-desaturase indicate that 27.5% of trans-11 18:1 administered was converted to cis-9, trans-11 CLA, consistent with previous estimates of 24.6 to 28.9% (Mosley et al., 2006; Shingfield et al., 2007; Tyburczy et al., 2008). Despite differences between individual animals, breeds, and experimental approaches, a close agreement in the estimates of endogenous cis-9, trans-11 CLA synthesis provides further support that the action of
9-desaturase on trans-11 18:1 to cis-9, trans-11 CLA is essentially constant under most conditions in the lactating cow (Griinari and Bauman, 1999; Shingfield et al., 2007; Glasser et al., 2008a).
Reductions in milk fat in response to postruminal CLA infusion were also accompanied by decreases in milk fat cis-9 10:1/10:0 and cis-9 12:1/12:0 concentrations ratios that serve as a proxy for
9-desaturase (Bauman and Davis, 1974; Bernard et al., 2008), consistent with trans-10, cis-12 CLA downregulating
9-desaturase gene expression (Baumgard et al., 2002; Palmquist et al., 2005). Decreases in mammary lipogenesis to abomasal infusion of high doses of mixed CLA isomers or relatively pure trans-10, cis-12 CLA preparations are also typically associated with a reduction in milk fat cis-9 14:1/14:0, cis-9 16:1/16:0 and cis-9 18:1/18:0 concentration ratios (Shingfield and Griinari, 2007). However, changes in these specific substrate-product indices in milk in response to CLA infusion in this experiment were not significant, a finding which is both unexpected and difficult to reconcile because the cis-9 14:1/14:0 ratio in milk is thought to reflect mammary
9-desaturase activity (Bernard et al., 2008). Administration of treatment T181 had no significant effect on milk fat desaturase indices. In vitro studies have shown that incubations with trans-10 18:1 and trans-11 18:1 had no effect on
9-desaturase activity of murine hepatic microsomes (Park et al., 2000).
In conclusion, abomasal infusion of a mixture of 18:1 isomers containing trans-10 and trans-11 as major components decreased milk fat content and yield. Because of the use of a mixture of FAME it was not possible to establish a direct cause and effect, but considerations of the amount and established association of infused fatty acids with MFD implicated trans-10 18:1 as the isomer responsible. Further studies are required using relatively pure preparations of high availability in the small intestine to allow unambiguous conclusions to be drawn on the role of trans-10 18:1 on mammary lipogenesis during diet-induced MFD.
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
|
|
|---|
3 Current address: Pharma Marine AS, LKG Biotech Park, Terøy, 6280 Søvik, Norway. ![]()
Received for publication December 28, 2008. Accepted for publication May 19, 2009.
| REFERENCES |
|---|
|
|
|---|
9-desaturase. J. Nutr. 130:2285–2291.This article has been cited by other articles:
![]() |
N. McKain, K. J. Shingfield, and R. J. Wallace Metabolism of conjugated linoleic acids and 18 : 1 fatty acids by ruminal bacteria: products and mechanisms Microbiology, February 1, 2010; 156(2): 579 - 588. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |